TY - JOUR
T1 - Evaluation of a New Esophageal Stent for the Treatment of Malignant and Benign Esophageal Strictures
AU - Kim, Kun Yung
AU - Tsauo, Jiaywei
AU - Song, Ho Young
AU - Park, Jung Hoon
AU - Jun, Eun Jung
AU - Zhou, Wei Zhong
AU - Kim, Min Tae
N1 - Funding Information:
This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant Number: HI15C0484 to H.Y.S.).
Publisher Copyright:
© 2017, Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Purpose: To evaluate the efficacy and safety of the EGIS esophageal stent for treating malignant and benign esophageal strictures. Materials and Methods: Data of 73 patients (mean age 63.0 ± 11.9 years; 66 males) with malignant esophageal stricture and 16 patients (mean age 63.7 ± 9.5 years; 13 males) with benign esophageal stricture who received the EGIS esophageal stent (S&G Biotech, Seongnam, Korea) between October 2010 and April 2016 were obtained from a prospectively maintained electronic database. Results: Technical and clinical success rates were 100% (89/89). Stent malfunction (i.e., tumor/tissue overgrowth, stent migration, and food impaction) occurred in 20.5% (15/73) and 37.5% (6/16) of patients with malignant and benign esophageal strictures, respectively. Stent migration occurred in five (6.8%) and four (25%) patients with malignant and benign esophageal strictures, respectively. The median follow-up durations in patients with malignant and benign esophageal strictures were 130 [interquartile range (IQR) 76–322] days and 486 (IQR 315–736) days, respectively. Recurrent dysphagia occurred in 14.1% (10/73) and 87.5% (14/16) of patients with malignant and benign esophageal strictures, respectively. The median recurrence-free durations in patients with malignant and benign esophageal strictures were 126 (IQR 69–259) days and 100 (IQR 40–182) days, respectively. Conclusion: The EGIS esophageal stent appears to be effective for malignant esophageal strictures, with relatively low rate of stent migration, whereas, for benign esophageal strictures, it seems to be associated with a high rate of recurrent dysphagia, mainly due to stent migration.
AB - Purpose: To evaluate the efficacy and safety of the EGIS esophageal stent for treating malignant and benign esophageal strictures. Materials and Methods: Data of 73 patients (mean age 63.0 ± 11.9 years; 66 males) with malignant esophageal stricture and 16 patients (mean age 63.7 ± 9.5 years; 13 males) with benign esophageal stricture who received the EGIS esophageal stent (S&G Biotech, Seongnam, Korea) between October 2010 and April 2016 were obtained from a prospectively maintained electronic database. Results: Technical and clinical success rates were 100% (89/89). Stent malfunction (i.e., tumor/tissue overgrowth, stent migration, and food impaction) occurred in 20.5% (15/73) and 37.5% (6/16) of patients with malignant and benign esophageal strictures, respectively. Stent migration occurred in five (6.8%) and four (25%) patients with malignant and benign esophageal strictures, respectively. The median follow-up durations in patients with malignant and benign esophageal strictures were 130 [interquartile range (IQR) 76–322] days and 486 (IQR 315–736) days, respectively. Recurrent dysphagia occurred in 14.1% (10/73) and 87.5% (14/16) of patients with malignant and benign esophageal strictures, respectively. The median recurrence-free durations in patients with malignant and benign esophageal strictures were 126 (IQR 69–259) days and 100 (IQR 40–182) days, respectively. Conclusion: The EGIS esophageal stent appears to be effective for malignant esophageal strictures, with relatively low rate of stent migration, whereas, for benign esophageal strictures, it seems to be associated with a high rate of recurrent dysphagia, mainly due to stent migration.
KW - Esophageal neoplasm
KW - Esophageal stricture
KW - Self-expandable metallic stent
UR - http://www.scopus.com/inward/record.url?scp=85019597705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019597705&partnerID=8YFLogxK
U2 - 10.1007/s00270-017-1677-2
DO - 10.1007/s00270-017-1677-2
M3 - Article
C2 - 28516274
AN - SCOPUS:85019597705
VL - 40
SP - 1576
EP - 1585
JO - Cardiovascular Radiology
JF - Cardiovascular Radiology
SN - 0174-1551
IS - 10
ER -